Naik Teja D, Tubaki Basavaraj R, Patankar Devayani S
Department of Kayachikitsa, Shri BMK Ayurveda Mahavidyalaya, A Constituent Unit of KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590003, India.
Department of Kayachikitsa, Shri BMK Ayurveda Mahavidyalaya, A Constituent Unit of KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590003, India.
J Ayurveda Integr Med. 2023 Jan-Feb;14(1):100592. doi: 10.1016/j.jaim.2022.100592. Epub 2022 Nov 9.
Irritable bowel syndrome (IBS) is one of the clinically challenging disorders. It has a significant effect on health, cost and quality of life. Ayurveda management through whole system approach in IBS is explored.
To evaluate the efficacy of whole system Ayurveda approach in IBS.
The present trial is a randomized controlled parallel group study. 48 patients diagnosed as IBS (Rome IV Criteria) between the age group of 20-60 yrs were recruited in the study. Patients were randomly divided into 2 groups. KC group intervened with Kalingadi Churna 3 gm twice a day, before food with buttermilk. WS group intervened with whole system ayurveda protocol (WSAP). Duration of intervention was 60 days with follow up on every 15th day. Assessments were through various clinical measures like IBS Symptom Severity Score (IBS-SSS), IBS Adequate Relief (IBS-AR), Gastrointestinal symptom rating scale (GSRS), IBS-VAS, Complete Spontaneous Bowel Movements (CSBMs), Bristol Stool Form (BSF), Hamilton Anxiety Rating Scale (HARS), Hamilton Depression Rating Scale (HDRS), IBS quality of life (IBS-QoL) at every follow up. Hemoglobin, Erythrocyte sedimentation rate and stool examination was conducted at pre and post study.
Study showed that WS group had significant improvement compared to KC group in IBS-SSS, IBS-AR, IBS-VAS, CSBM, BSF-Diarrhea and BSF-Constipation. Both groups were comparable in GSRS, HARS, HDRS and IBS-QOL. Blood and stool parameters assessments showed comparable improvements in both the groups. Within group significant improvements in all the clinical assessment scales were observed in both the groups.
WSAP was effective in management of IBS (IBS constipation and IBS diarrhea). Improvements were observed in abdominal pain, stool frequency, consistency and adequate relief.
肠易激综合征(IBS)是临床上具有挑战性的疾病之一。它对健康、成本和生活质量有重大影响。本文探讨了阿育吠陀整体系统疗法对肠易激综合征的治疗效果。
评估阿育吠陀整体系统疗法对肠易激综合征的疗效。
本试验为随机对照平行组研究。招募了48名年龄在20至60岁之间、被诊断为肠易激综合征(符合罗马IV标准)的患者。患者被随机分为两组。KC组每天两次,每次3克卡林加迪药粉,饭前与酪乳一起服用。WS组采用阿育吠陀整体系统疗法方案(WSAP)进行干预。干预持续时间为60天,每15天进行一次随访。通过各种临床指标进行评估,如肠易激综合征症状严重程度评分(IBS-SSS)、肠易激综合征充分缓解率(IBS-AR)、胃肠道症状评分量表(GSRS)、肠易激综合征视觉模拟量表(IBS-VAS)、完全自主排便次数(CSBMs)、布里斯托大便分型(BSF)、汉密尔顿焦虑评定量表(HARS)、汉密尔顿抑郁评定量表(HDRS)、每次随访时的肠易激综合征生活质量(IBS-QoL)。在研究前后进行血红蛋白、红细胞沉降率和粪便检查。
研究表明,与KC组相比,WS组在IBS-SSS、IBS-AR、IBS-VAS、CSBM、BSF-腹泻型和BSF-便秘型方面有显著改善。两组在GSRS、HARS、HDRS和IBS-QOL方面具有可比性。血液和粪便参数评估显示两组有类似的改善。两组在所有临床评估量表上均观察到组内显著改善。
WSAP对肠易激综合征(便秘型和腹泻型)的治疗有效。在腹痛、大便频率、性状及充分缓解方面均有改善。